In terms of accounts receivable, days sales outstanding for the fourth quarter ... And we do expect that with some favorable product and customer mix going into 2025, we should see an improvement ...

Goldman Sachs analyst Salveen Richter highlights potential benefits for biopharma from 340B reforms, while Medicaid cuts could pose risks for companies with significant drug exposure.

The 340B program, once a lifeline for underserved communities, has become a case study in crony capitalism. Designed to help hospitals serving low-income patients by offering discounted ...

Regarding “New Jersey hospitals exploit 340B at the expense of patients,” NorthJersey.com, Jan. 17: Everyone can relate to the high price of prescription drugs — including hospitals ...

Widespread and longstanding abuse of a federal program designed to provide prescription drugs to low-income patients has prompted lawmakers in Minnesota and Michigan to try to rein in the 340B program ...

The federal 340B Drug Pricing Program allows certain hospitals and clinics to buy medications given to outpatients at a discount, then bill patients and insurers the full price — keeping the ...

Find this week’s updates on 340B litigation to help you stay in the know on how 340B cases are developing across the country. Each week we comb through the dockets of more than 50 340B cases to ...

As pharmaceutical companies push back against the 340B Drug Pricing Program, several states, including Utah, Colorado, Arkansas, Maine and Nebraska, are introducing legislation to protect the ...

For now, though, a new report helps inform what we should expect from the sales mix for different iPhone 16 models. CIRP published a new report today that provides a breakdown of iPhone sales from ...

Residential energy technology sales are anticipated to reach $300 million to $400 million in 2025, supported by the launch of PWRcell 2 and other ecosystem products. Fourth quarter adjusted EPS was $2 ...